Krishna Institute of Medical Sciences Limited – Investor Presentation Summary

Key Operational Highlights

  • IP Volume: 81,668 in Q2 FY27 (up 27.0% YoY), 154,161 in H1 FY27 (up 26.8% YoY)
  • OP Volume: 731,010 in Q2 FY27 (up 23.3% YoY), 1,389,627 in H1 FY27 (up 25.7% YoY)
  • ARPOB: ₹48,277 in Q2 FY27 (up 14.9% YoY), ₹47,768 in H1 FY27 (up 12.4% YoY)
  • ARPP: ₹165,577 in Q2 FY27 (up 9.9% YoY), ₹164,635 in H1 FY27 (up 8.5% YoY)
  • ALOS: 3.43 days in Q2 FY27, 3.45 days in H1 FY27
  • Bed Capacity: 7,459 beds as of Q2 FY27
  • Operational Beds: 5,605 beds as of Q2 FY27
  • Occupied Beds: 3,045 in Q2 FY27, Occupancy: 54.3%

Key drivers of operational performance: Expansion across multiple states, deployment of advanced medical technology, and increased patient volumes across both inpatient and outpatient services.

Segment-wise Performance

Telangana (Secunderabad, Kondapur, Gachibowli, Begumpet, MIPPL and Asian Transcare):

  • Total Revenue: ₹7,019 million in Q2 FY27
  • EBITDA: ₹1,892 million in Q2 FY27 (27.0% margin)
  • IP Volume: 28,272 in Q2 FY27
  • OP Volume: 265,813 in Q2 FY27
  • ARPOB: ₹75,731
  • Occupancy: 49.7%

Andhra Pradesh (Nellore, Rajahmundry, Srikakulam, Ongole, Vizag, Anantapur, Kurnool):

  • Total Revenue: ₹2,882 million in Q2 FY27
  • EBITDA: ₹556 million in Q2 FY27 (19.3% margin)
  • IP Volume: 30,412 in Q2 FY27
  • OP Volume: 215,630 in Q2 FY27
  • ARPOB: ₹26,113
  • Occupancy: 61.1%

Maharashtra (Nagpur, Nashik, Thane):

  • Total Revenue: ₹1,790 million in Q2 FY27
  • EBITDA: ₹290 million in Q2 FY27 (16.2% margin)
  • IP Volume: 10,536 in Q2 FY27
  • OP Volume: 76,712 in Q2 FY27
  • ARPOB: ₹44,595
  • Occupancy: 62.6%

Keralam (Kannur, Kollam, Palakkad):

  • Total Revenue: ₹833 million in Q2 FY27
  • EBITDA: ₹105 million in Q2 FY27 (12.6% margin)
  • IP Volume: 8,425 in Q2 FY27
  • OP Volume: 109,157 in Q2 FY27
  • ARPOB: ₹30,470
  • Occupancy: 48.1%

Karnataka (Bengaluru - Mahadevapura and Electronic City):

  • Total Revenue: ₹1,106 million in Q2 FY27
  • EBITDA: ₹(54) million in Q2 FY27 (-4.9% margin)
  • IP Volume: 4,023 in Q2 FY27
  • OP Volume: 63,698 in Q2 FY27
  • ARPOB: ₹94,983
  • Occupancy: 36.8%

Explanation of significant changes in segment performance: Telangana continues to be the highest revenue contributor with premium pricing, while newer units in Maharashtra and Keralam are showing improved occupancy and margin progression. Karnataka units are still in ramp-up phase.

Financial Highlights

Revenue: ₹13,630 million in Q2 FY27

EBITDA: ₹2,789 million in Q2 FY27 (20.5% margin)

PAT: ₹757 million in Q2 FY27 (5.6% margin)

EPS: ₹1.81 (Basic and Diluted) in Q2 FY27

Margins: EBITDA margin 20.5%, PAT margin 5.6% in Q2 FY27

YoY/QoQ comparison: Revenue up 41.3% YoY and 14.0% QoQ; EBITDA up 34.0% YoY and 16.3% QoQ; PAT up 5.1% YoY and 102.4% QoQ

Drivers of financial performance: Higher patient volumes, improved ARPOB, expansion of bed capacity, and operational efficiency improvements.

EBITDA before IND AS 116: ₹2,502 million in Q2 FY27 (up 24.6% YoY)

PBT and PAT include (Loss)/gain on fair valuation of Call option (net) ₹132 million in Q2 FY27 and share of profit from associate net of tax ₹7 million in Q2 FY27.

Geographical Revenue Split

Domestic Revenue: 100% domestic operations (all units located in India)

Regional Breakdown:

  • Telangana: ₹13,253 million in H1 FY27 (51.8% of total)
  • Andhra Pradesh: ₹5,517 million in H1 FY27 (21.6% of total)
  • Maharashtra: ₹3,294 million in H1 FY27 (12.9% of total)
  • Keralam: ₹1,609 million in H1 FY27 (6.3% of total)
  • Karnataka: ₹1,916 million in H1 FY27 (7.5% of total)

Balance Sheet Snapshot

Not Specified

Capex & Cash Flow Health

Capital Expenditure: Not Specified

Free Cash Flow: Not Specified

Operating Cash Flow: Not Specified

Net Debt Movement: Not Specified

Investment Rationale: Focus on capacity expansion through greenfield projects, acquisitions, and O&M opportunities, adding 700+ beds.

Strategic & R&D Initiatives

Investments in Innovation: Deployment of advanced medical technology including 4-Arm HD da Vinci Robotic Surgical System, MrGFUS Focussed Ultrasound, Mako Robotic for Knee Replacement, ESWL Dornier, Tulsa-Pro System, and Gamma Knife.

Expected impact on growth: Enhanced capability for complex surgeries, improved patient outcomes, and differentiation in competitive markets.

Strategic Rationale: Establishing dominant presence in target geographies, building long-term doctor partnerships through equity participation, and delivering affordable quality care.

Industry Trends & Business Environment

Macro/Industry Trends: Growing demand for healthcare services, increasing adoption of advanced medical technology, expansion of healthcare infrastructure in tier 2 and 3 cities.

Impact on Company: Opportunities for market share gains through strategic expansion, ability to command premium pricing for advanced procedures, and benefits from demographic trends driving healthcare demand.

Management Commentary & Growth Outlook

Strategic Outlook: Focus on consistent growth achieved through 26%+ CAGR in Revenue and 28%+ CAGR in EBITDA over 2 decades, reflecting sustained operational excellence and strategic expansion.

FY Guidance: Not explicitly specified, but the presentation emphasizes continued expansion with planned additions in Rajahmundry II (350 beds), Ongole (50 beds), and Chennai (300 beds).

Market Share Targets: Aim to be Number 1 player in Organ transplantation specialty (Heart, Lung, Liver and Kidney) and maintain leadership positions in various specialties across operating regions.

Risks and Opportunities: Not explicitly specified in the presentation.